MEGIN
  • About us
    • About us
    • Meet the team
  • Our solution
    • MEG Maps™ powered by TRIUX™ neo
    • Book a MEG Maps™ Demo
  • News & Education
    • News
    • MEGIN Spotlights
    • MEGIN Masterclass
    • Abstracts and studies
  • Patients
  • Find a MEG site
    • Global
    • North America
  • Get in touch
    • Contact us
    • Book a MEG Maps™ Demo
Select Page
MEGIN is proud to enter into a strategic partnership with FIND Neuro, a Mass General Hospital backed organization

MEGIN is proud to enter into a strategic partnership with FIND Neuro, a Mass General Hospital backed organization

by MEGIN | Dec 2, 2023 | MEGIN News

MEGIN is delighted to announce a partnership with FIND Neuro, a disruptive start-up that reconstructs brain network maps to enable treatment of neurological diseases. FIND Neuro originated at Mass General Hospital and was co-founded by Dr. Noam Peled (CEO), Prof...
MEGIN announces sale and installation of TRIUX™ neo to Simon Fraser University

MEGIN announces sale and installation of TRIUX™ neo to Simon Fraser University

by MEGIN | Oct 5, 2023 | MEGIN News

HELSINKI, FINLAND (October 5, 2023) – MEGIN is delighted to announce the sale and installation of our latest magnetoencephalography (MEG) technology, the TRIUX™ neo, to Simon Fraser University’s (SFU) core facility, ImageTech Lab. Located in British Columbia,...
Hiroshima University announces the sale of the first TRIUX™ neo in Japan

Hiroshima University announces the sale of the first TRIUX™ neo in Japan

by MEGIN | Jul 3, 2023 | MEGIN News

Hiroshima University Hospital press release – an announcement from our customer-partner   Hiroshima University Hospital established its Epilepsy Center in January 2014. The Epilepsy Center has since been responsible for providing tertiary medical care as part of the...
Fixel Institute expands care with new neuroimaging and clinical research suites

Fixel Institute expands care with new neuroimaging and clinical research suites

by MEGIN | Apr 27, 2023 | MEGIN News

A 15,000-square-foot neuroimaging suite that includes four high-tech imaging machines — including one of just three in the Southeast — opened Monday as the Norman Fixel Institute for Neurological Diseases at UF Health moves into a new phase of its growth. In addition...
MEGIN’s latest global customer survey finds customers are extremely satisfied with the customer service, project management and installation offered by MEGIN

MEGIN’s latest global customer survey finds customers are extremely satisfied with the customer service, project management and installation offered by MEGIN

by MEGIN | Mar 1, 2023 | MEGIN News

Earlier this year, as part of its commitment to continually improving its customer service, MEGIN partnered with B2B international – a full-service market research company, to issue a global satisfaction survey to its customers, looking closely at the service MEGIN...
Bridging the gap: Adopting innovative technology in UK clinical settings

Bridging the gap: Adopting innovative technology in UK clinical settings

by MEGIN | Jan 30, 2023 | Epilepsy, MEGIN News

The role of Magnetoencephalography (MEG) technology, its clinical use in the UK, and a vision for the future. Stefano Seri, emeritus professor of clinical neurophysiology at the IHN (pictured below), said the technology could help to support thousands of patients in...
« Older Entries
Next Entries »

Home
About us

MEG Maps™
Contact us
Subscribe to the newsletter

Insights & Education

News
MEGIN Spotlights
MEGIN Masterclass
Abstracts & studies

Patients

MEGIN China

Find a MEG site
Global
North America

Connect with us
  • Follow
  • Follow
  • Follow

Copyright 2026© – MEGIN
MEGIN’s new platform MEG Maps™ is powered by TRIUX™ neo and MEGreview™, which have 510(k) clearance from the US Food & Drug Administration (FDA) and are under EU MDR Notified body review, i.e. not available for commercial distribution in the EU area. For commercial distribution, please contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician
.